|
- OPDIVO® (nivolumab)
OPDIVO ® (nivolumab) is a prescription medicine used in combination with YERVOY ® (ipilimumab) to treat adults with a type of liver cancer called hepatocellular carcinoma (HCC) when your liver cancer cannot be removed by surgery or has spread, and you have received prior treatment with sorafenib
- Frequently Asked Questions (FAQ) | OPDIVO® (nivolumab)
Find answers to frequently asked questions about OPDIVO® (nivolumab) including what OPDIVO® is, how immunotherapy works, and what are the side effects of OPDIVO®
- Subcutaneous Injection Immunotherapy Treatment| OPDIVO Qvantig . . .
Learn more about OPDIVO Qvantig™ (nivolumab+hyaluronidase-nvhy) as a subcutaneous injection immunotherapy treatment option for your fight against cancer Please see Indication and Important Safety Information
- OPDIVO® Support Patient Resources | OPDIVO® (nivolumab)
Whether you're a new or continuing OPDIVO® (nivolumab) patient, find resources that can support you through a cancer diagnosis and during treatment Access helpful resources and find assistance for OPDIVO® patients here Please see Indication and Important Safety Information
- Classical Hodgkin Lymphoma (cHL) Cancer Treatment | OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a treatment option for certain adults with previously treated classical Hodgkin lymphoma (cHL) whose cancer has come back or spread Please see Indication and Important Safety Information
- Clinical trial results for - OPDIVO
See how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) performed in a clinical trial as first-line treatment for adults with stage 4 or recurrent advanced non-small cell lung cancer that tested positive for PD-L1
- OPDIVO with You | Patient Caregiver Support Program Registration . . .
Sign up for OPDIVO with You, a support program that offers helpful information if you are about to start or are currently on OPDIVO® (nivolumab) or an OPDIVO®-based combination
- Patient and Caregiver Stories | OPDIVO® (nivolumab)
Watch videos of real OPDIVO® (nivolumab) patients and caregivers Learn more about patients' diagnoses and treatment experiences Please see Indication and Important Safety Information
|
|
|